Role of SIK3 in PKA/mTORC1 regulation of adipose browning

SIK3 在 PKA/mTORC1 调节脂肪褐变中的作用

• 批准号: 10736962
• 负责人: SHEILA COLLINS
• 金额: $ 54.08万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-06 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10736962
• 关键词: Adipocytes; Adipose tissue; Adrenergic Agents; Adult; Affect; Agonist; Amino Acids; Behavioral; Biogenesis; Biology; Body Temperature; Body fat; Body mass index; Brown Fat; Calories; Cardiometabolic Disease; Cardiovascular Diseases; Cell Culture Techniques; Cells; Chronic; Chronic Disease; Complex; Consumption; Country; Critical Pathways; Cyclic AMP; Cyclic AMP Receptor Protein; Cyclic AMP-Dependent Protein Kinases; Data; Desire for food; Disease; Economics; Energy Metabolism; Epidemic; Event; FDA approved; FRAP1 gene; Fatty Acids; Fatty acid glycerol esters; Gatekeeping; Gene Expression; Gene Expression Profile; Genes; Genetic Models; Genetic Transcription; Glucose; Goals; HDAC4 gene; Histone Deacetylase; In Vitro; Incidence; Individual; Insulin Resistance; Isoproterenol; Knockout Mice; Knowledge; Life Style; Link; Location; Medical; Metabolic Diseases; Metabolic syndrome; Metabolism; Mitochondria; Modeling; Molecular; Nature; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Obesity Epidemic; Overweight; PPAR gamma; Pathway interactions; Peripheral; Pharmaceutical Preparations; Pharmacology Study; Phosphorylation; Phosphorylation Site; Population; Production; Proteins; Protons; Public Health; Quality of life; Receptor Activation; Receptor Signaling; Regulation; Research; Respiration; Risk; Rodent; Role; Safety; Signal Pathway; Signal Transduction; Sirolimus; Stable Isotope Labeling; Sympathetic Nervous System; Testing; Therapeutic; Tissue Model; Triglycerides; Work; absorption; beta-adrenergic receptor; cardiometabolic risk; cold temperature; cost; diet-induced obesity; economic impact; experimental study; genetic signature; genome-wide; improved; in vivo; inhibitor; insulin sensitivity; knock-down; link protein; metabolic phenotype; metabolic respiration; novel strategies; obesity treatment; overexpression; p38 Mitogen Activated Protein Kinase; pharmacologic; phosphoproteomics; prevent; programs; recruit; response; salt-inducible kinase; small hairpin RNA; small molecule; uncoupling protein 1

Project Summary: . Obesity is at epidemic proportions in the US. Over 60% of the population is either overweight (Body Mass Index [BMI] ≥25 to <30 kg/m2) or obese (BMI ≥30 kg/m2), placing them at risk for a large number of chronic diseases, including insulin resistance, metabolic syndrome, and type 2 diabetes. The annual costs of obesity exceed $100 billion, making it one of the most significant public health and economic issues facing the country. Unfortunately, the treatment of obesity is unsatisfactory. Lifestyle and behavioral approaches have a modest, and often transient, effect while FDA-approved therapeutic options targeting appetite or fat absorption have poor tolerability and, in some cases, safety concerns. Thus, there is a critical need for novel approaches to treat obesity. Agents acting via peripheral mechanisms to increase energy expenditure would be valuable. The sympathetic nervous system (SNS) is well-known as an activator of brown adipose tissue (BAT) and the “browning” of cells in white adipose tissue (WAT) depots to increase uncoupled mitochondrial respiration and energy expenditure. Our earlier work established signaling cascades from β-adrenergic receptors (βARs)  cAMP  protein kinase A (PKA)  p38 MAP kinase (MAPK), and also from PKA to mTORC1. These downstream signaling modules are key to drive the transcription of brown adipocyte genes such as uncoupling protein-1 (UCP1), PPAR-gamma coativator-1α (PGC-1α), and the broader program of mitochondrial biogenesis. The Scientific Premise of this project is based upon our identification of substrates of PKA- activated mTORC1 that convey the brown-adipose promoting machinery, and we will determine their molecular mechanisms. Our long-term goal is to define signaling pathways that are critical to metabolic and cardiovascular disease and, using this knowledge, to target pivotal components of these signaling pathways to prevent or reverse the diseases.

项目摘要：。 在美国，肥胖症的流行程度很高。超过60%的人口要么超重(身体质量 体重指数[BMI]≥25至30 kg/m2)或肥胖(BMI≥30 kg/m2)，使他们面临患上大量慢性 疾病，包括胰岛素抵抗、代谢综合征和2型糖尿病。肥胖症的年度成本 超过1000亿美元，使其成为该国面临的最重要的公共卫生和经济问题之一。 不幸的是，肥胖症的治疗并不令人满意。生活方式和行为方式有适度的， 通常是暂时的，而FDA批准的针对食欲或脂肪吸收的治疗方案有 耐受性差，在某些情况下，安全问题。因此，迫切需要新的方法来 治疗肥胖症。通过外围机制来增加能量消耗的代理将是有价值的。这个 交感神经系统(SNS)是众所周知的棕色脂肪组织(BAT)的激活剂，而 白色脂肪组织(WAT)储存库中细胞的“褐变”，以增加未偶联的线粒体呼吸和 能源支出。我们早期的工作建立了β-肾上腺素能受体(β-AR)的信号级联 CAMP蛋白激酶A(cAMPProtein Kinase A，PKA)是p38的MAPK，也是从PKA到mTORC1.这些 下游信号模块是驱动棕色脂肪细胞基因转录的关键，如解偶联 蛋白-1(UCP1)、PPAR-γCoativator-1α(PGC-1α)，以及更广泛的线粒体程序 生物发生学。这个项目的科学前提是基于我们对PKA底物的识别- 激活的mTORC1传递棕色脂肪促进机制，我们将确定它们的分子 机制。我们的长期目标是定义对新陈代谢和 心血管疾病，并利用这一知识，针对这些信号通路的关键组件 预防或逆转疾病。